Pharmacologic management of mesenteric occlusive disease

William H. Frishman, Sofia Novak, Lawrence J. Brandt, Adam Spiegel, Andrew Gutwein, Maureen Kohi, Grigory Rozenblit

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Mesenteric vascular disease has been diagnosed increasingly over the past 25 years. This rise in incidence has been attributed to the advanced mean age of the population, an increasing number of critically ill patients and a greater clinical recognition of the condition. Although surgical revascularization and resection has long been the standard of treatment, medical management can also play an important adjunctive role. Early diagnosis before irreversible bowel damage, which may occur within 6-8 hours after the insult, is necessary to improve survival and reduce morbidity. Even in the presence of irreversible bowel ischemia, perioperative medical treatment may reduce disease progression, enabling more limited bowel resection. This article outlines the appropriate pharmacologic management of ischemic disorders of the intestine, with an emphasis on the pharmacologic treatments presently being used in clinical practice and those being studied in the laboratory.

Original languageEnglish (US)
Pages (from-to)59-68
Number of pages10
JournalCardiology in review
Issue number2
StatePublished - Mar 2008


  • Acute/chronic mesenteric ischemia
  • Colon ischemia
  • Mesenteric vascular disease
  • Mesenteric venous thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pharmacologic management of mesenteric occlusive disease'. Together they form a unique fingerprint.

Cite this